Study summary
Talazoparib plus enzalutamide helped men live about 9 months longer
45.8months median survival, vs 37.0 with enzalutamide alone
What was tested
Talazoparib, a PARP inhibitor, plus enzalutamide against enzalutamide alone as first treatment for metastatic castration-resistant prostate cancer, whether or not DNA-repair genes were altered.
What they found
- Median overall survival was 45.8 vs 37.0 months.
- The benefit was larger in men with DNA-repair gene changes.
What it means
Supports a PARP inhibitor combination as a first choice once prostate cancer becomes castration-resistant.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.